 "Lupin launches generic Duexis tablets in US to treat rheumatoid arthritis")
Drug firm Lupin on Wednesday said it has launched generic Duexis tablets used to treat the symptoms of rheumatoid arthritis and osteoarthritis in the US market.
The company has launched an authorised generic version of Horizon Medicines LLC's Duexis (ibuprofen and famotidine) tablets, 800 mg/26.6 mg, Lupin said in a regulatory filing.
According to IQVIA MAT July 2021, ibuprofen and famotidine tablets (reference listed drug Duexis) had an estimated annual sales of USD 765 million in the US, it added.
The product, "is indicated for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer in patients who are taking ibuprofen for those indication," Lupin said.
Shares of Lupin Ltd were trading at Rs 989.35 per scrip on BSE, up 0.76 per cent from its previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app